Sensei Biotherapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Sensei Biotherapeutics files an amendment to its 2025 10-K report, primarily to update Item 1. Business section and include revised Section 302 certifications.
NASDAQ
Sensei BioTherapeutics streamlines operations to prioritize clinical development of solnerstotug, extending its financial runway into the second quarter of 2026.
NASDAQ
Sensei Biotherapeutics reports its 2023 financial results, highlighting progress in its clinical pipeline and extending its cash runway into the fourth quarter of 2025.